Gliken

Gliken is an oral prescription medication that contains the active ingredient glibenclamide, a sulfonylurea used to manage blood glucose in adults with type 2 diabetes mellitus. It is marketed in the European Union and is supplied in tablet form (strength varies by manufacturer). Gliken works by stimulating insulin release from pancreatic beta‑cells, helping to lower elevated blood sugar levels as part of a comprehensive diabetes management plan.

Gliken is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

- Improves fasting and post‑prandial blood glucose levels. - Can be used as monotherapy in patients newly diagnosed with type 2 diabetes. - May be combined with metformin or other oral antidiabetic agents when additional glucose lowering is required. - Often prescribed when a sulfonylurea is preferred due to cost or patient response considerations. - May be considered in patients with stable renal function who do not require insulin therapy.

The safety profile of Gliken reflects the typical effects observed with sulfonylurea class medications.

Common: - Mild to moderate hypoglycemia, often occurring when meals are missed, delayed, or when alcohol is consumed. - Gastrointestinal discomfort such as nausea, abdominal pain, dyspepsia, or loss of appetite. - Gradual weight gain related to increased insulin secretion and caloric intake. - Dermatologic reactions including rash, pruritus, or mild urticaria.

Serious: - Severe hypoglycemia that may cause confusion, seizures, loss of consciousness, or require emergency medical assistance. - Allergic responses ranging from skin rash to angioedema and, in rare cases, anaphylactic shock. - Hepatotoxicity presenting as jaundice, elevated transaminases, or hepatitis (uncommon). - Acute pancreatitis characterized by persistent abdominal pain, nausea, and raised pancreatic enzymes (rare).

When prescribing Gliken, clinicians consider several precautions to minimize risk and ensure safe use.

- Assess renal and hepatic function before initiation and periodically during therapy. - Use lower starting doses in elderly patients or those with reduced clearance. - Advise patients to maintain regular meal patterns to avoid hypoglycemia. - Monitor for signs of cardiovascular disease, as sulfonylureas may mask ischemic symptoms. - Counsel women of childbearing potential about pregnancy risks and recommend effective contraception. - Review concomitant medications for agents that potentiate hypoglycemia, such as certain antibiotics or antiretrovirals. - Educate patients on recognizing early symptoms of hypoglycemia and appropriate corrective actions.

Gliken may interact with other medicines, affecting blood glucose levels or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or meglitinides, which can cause additive hypoglycemia. - Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glibenclamide plasma concentrations. - Combining with insulin or high‑dose metformin without dose adjustment, due to heightened hypoglycemic risk. - Avoid use with high‑dose corticosteroids, which may exacerbate hyperglycemia and counteract Gliken's effect.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can alter glucose tolerance. - Oral contraceptives, as hormonal changes may affect glycemic control. - Renal impairment drugs such as ACE inhibitors may require dose modification and closer monitoring.